NeurExo Sciences and Henry Ford Health System Announce Upcoming Presentations on Exosomes in Stroke at 45th International Stroke Conference February 6-8

ATLANTA and DETROIT and HONOLULU, Jan. 31, 2019 /PRNewswire/ -- NeurExo Sciences, LLC (NXS), a biotechnology company focused on the development of exosome therapies, and Henry Ford Health System (HFHS), a non-profit organization, today announced that HFHS will be presenting new data on exosomes and stroke in several oral presentations and posters at the American Stroke Association 45^th International Stroke Conference (ISC), being held Feb. 6-8, 2019 in Honolulu, Hawaii.

The presenting researchers are all from the laboratory of Michael Chopp, Ph.D., Vice Chairman, Department of Neurology; Scientific Director, Neurosciences Institute; Zoltan J. Kovacs Chair of Neuroscience Research at Henry Ford Health System in Detroit; and Distinguished Professor of Physics at Oakland University in Rochester, Michigan.

Exosome Presentation Details

Special Symposium – Cell Therapies for Stroke

Oral Presentation: Exosomes derived from ischemic cerebral endothelial cells promote axonal growth.  Zhang Y, Chopp M, Li C, Liu X, Wang X, Zhang L, Zhang ZG.

Oral Presentation: Brain-Heart interaction after stroke: Therapeutic effects of exosomes in type 2 diabetic mice subjected to stroke.  Venkat P, Cui C, Xu J, Zacharek A, Yang XP, Chopp M, Wang F, Landschoot-Ward J, Chen J.

Moderated Poster Presentation: Brain-derived microparticles mediates cardiac dysfunction after stroke.  Chen Z, Yan T, Yang S, Li W, Wu H, Zacharek A, Venkat P, Chopp M, Zhang J, Chen J.

Moderated Poster Presentation: MiR-17-92 cluster enriched MSC exosomes promote myelination and axonal extension which contribute to increased EMG conduction and functional recovery after stroke in rats.  Xin H, Liu Z, Buller B, Li Y, Golembieski W, Gan X, Wang F, Shang X, Zhang ZG, Chopp M.

Poster Presentation: Overexpression of miR-133b in reactive astrocytes enhances their released exosomes which contribute to neurite remodeling and functional recovery after stroke.  Liu Z, Chopp M, Li Y, Gan X, Wang F, Shang X, Zhang ZG, Xin H.

In addition, the HFHS team has other presentations at ISC, bringing their total to eight. 

Teach In: Enriched Exosomes, a Novel Therapeutic Approach – February 12, 2019 in New York

NeurExo Sciences also will host an exosome teach-in event In New York City on Tuesday, Feb. 12 from 8:00 – 9:30 a.m. featuring Dr. Chopp and members of his research team, who will be available to answer questions. The live event is open to institutional/venture investors, sell-side analysts, investment bankers, and business development professionals. If you are interested in attending, please contact Susan Pietropaolo ([email protected]; 201-923-2049) for more information. The presentation will also be webcast and can be accessed here.

About Exosomes

Exosomes are small extracellular vesicles that transport DNA, RNAs, lipids and proteins between cells, allowing organs, tissues and cells to communicate with one another and elicit specific biological responses based on their cargo. MicroRNAs transported by exosomes regulate gene translation and play primary roles in mediating a vast array of biological functions, including immunomodulation and the potential to enable multiple pathways of neurovascular restoration.

About the Chopp Lab in the Department of Neurology and the Neurosciences Institute at Henry Ford Hospital

Dr. Chopp is dedicated to translational research in neuroscience, and he and his group are recognized as foremost authorities on exosomes and microRNA for treatment of neurological injury and disease.  The focus of the laboratory is the pathophysiology of stroke and traumatic brain injury; mechanisms of neuroprotection, and cell-based, biologic (e.g. exosomes), molecular and pharmacological neurorestorative therapies for stroke, traumatic brain injury, and neurodegenerative disease. Dr. Chopp has approximately 750 peer reviewed publications and has received numerous prestigious research awards. His laboratory, comprising 70 researchers and staff, is one of the leading research centers in the world in translational neuroscience and restorative neurology and was the first lab to use mesenchymal stem cells (MSCs) as well as exosomes derived from MSCs and other sources, to treat stroke, TBI, and neurodegenerative diseases. His lab has been awarded more than $80 million in total funding and has 19 active NIH grants.

About NeurExoSciences

NeurExo Sciences, LLC, a privately-held biopharmaceutical company and subsidiary of NeuroTrauma Sciences, LLC, was formed in 2018 to advance Henry Ford's pioneering technology involving exosomes as extracellular vesicles enriched with microRNA for the purpose of treating stroke, traumatic brain injury (TBI) including concussion, and neuropathies.  NXS has worldwide commercial rights to product candidates resulting from the exosome and miRNA IP and sponsored research generated by the lab. 

For further information, please contact:

SOURCE NeurExo Sciences

Related Links

http://www.neurotraumasciences.com